No Data
No Data
Reported Saturday, Mirum Pharmaceuticals' LIVMARLI Data Presented At ESPGHAN, Featuring Key Findings On ALGS And PFIC
Presented by Professor Richard J. Thompson, MD, King's College London, United KingdomPatients with PFIC showed significant and sustained improvements in pruritus severity, serum bile acid (sBA) levels
Mirum Pharmaceuticals' LIVMARLI Data Showcased at ESPGHAN Annual Meeting
- Seven abstracts highlighting ALGS and PFIC data, including three oral presentations - Long-term extension data from Phase 3 MARCH-ON PFIC study presented at plenary session and selected among the highest scoring
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today announced that on May 10, 2024, the Compensation Committee of Mirum's Board of Directors granted inducement awards consisting of non-qualified stock options to purchase
Mirum Pharmaceuticals Inc (MIRM) Q1 2024 Earnings: Misses Revenue Forecasts, Posts Wider Net Loss
Mirum Pharmaceuticals Is Maintained at Overweight by Morgan Stanley
Mirum Pharmaceuticals Is Maintained at Overweight by Morgan Stanley
Morgan Stanley Maintains Overweight on Mirum Pharmaceuticals, Lowers Price Target to $53
Morgan Stanley analyst Michael Ulz maintains Mirum Pharmaceuticals with a Overweight and lowers the price target from $57 to $53.
No Data
The Real Wojak : Do you have like a top 3-5 that you like more than all the other ones? This list is way too long